Invictus RG’s Supernus Pharmaceuticals SUPN Stock Holding History

Invictus RG’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,190	Closed	-$257K	–	821
2016 Q4	$257K	Buy	+10,190	New	+$228K	0.17%	236

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Invictus RG's SUPN Position: Q1 2017 in Review

Invictus RG sold out of Supernus Pharmaceuticals (SUPN) in Q1 2017, closing a stake of 10,190 shares — an estimated $257K sold.

Invictus RG first reported a position in SUPN in Q4 2016 and held it in 1 quarter. The position peaked at $257K in Q4 2016. 246 funds tracked by Wall St. Rank hold SUPN as of Q1 2017.

Invictus RG reported no remaining Supernus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Invictus RG sold 10,190 Supernus Pharmaceuticals shares in Q1 2017, an estimated $257K.
Invictus RG first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Invictus RG's Supernus Pharmaceuticals position peaked at $257K in Q4 2016.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2017.

Based on Invictus RG's 13F filing for Q1 2017, filed 12 May 2017.